Yahoo · Sep 9, 2026
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BL
NASDAQ · BLTE
Belite Bio, Inc
Healthcare · Biotechnology
$152.17
Up+$1.29 (+0.85%)
Updated Nov 4, 2026, 8:53 PM
SID Score
3.3/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 5.24B
- P/E ratio
- -99.11
- Dividend yield
- 0.00%
- 52-week range
- $130.00 – $198.58
- Volume
- 150.15K
- Avg. volume
- 136.46K
Price performance · BLTE
BLTE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BLTE closed at $152.17 after 21 trading sessions, down 2.21% for the selected period.
- Last close
- $152.17
- Period change
- -2.21%
- Period low
- $142.78
- Period high
- $158.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $154.47 | $157.4715 | $151.91 | $152.17 | 150.15K |
| Nov 2, 2026 | $155.08 | $157.00 | $150.67 | $153.67 | 114.88K |
| Oct 30, 2026 | $148.79 | $156.325 | $146.9002 | $154.74 | 234.88K |
| Oct 29, 2026 | $148.58 | $151.91 | $147.93 | $150.28 | 93.26K |
| Oct 28, 2026 | $144.99 | $148.72 | $143.71 | $148.72 | 81.95K |
| Oct 27, 2026 | $143.00 | $147.00 | $142.56 | $145.72 | 138.13K |
| Oct 26, 2026 | $149.12 | $149.12 | $142.125 | $143.35 | 137.15K |
| Oct 23, 2026 | $150.70 | $150.70 | $146.27 | $147.33 | 49.85K |
| Oct 22, 2026 | $153.14 | $154.425 | $149.50 | $150.27 | 125.66K |
| Oct 21, 2026 | $155.70 | $156.88 | $152.01 | $153.18 | 113.77K |
| Oct 20, 2026 | $148.69 | $156.04 | $148.155 | $154.45 | 209.74K |
| Oct 19, 2026 | $143.46 | $150.465 | $142.94 | $147.34 | 164.38K |
| Oct 16, 2026 | $152.62 | $152.62 | $141.62 | $142.78 | 193.84K |
| Oct 15, 2026 | $153.87 | $155.47 | $152.13 | $152.62 | 195.86K |
| Oct 14, 2026 | $151.17 | $155.085 | $150.02 | $152.72 | 158.5K |
| Oct 13, 2026 | $157.01 | $161.00 | $150.9325 | $151.87 | 233.36K |
| Oct 12, 2026 | $154.95 | $160.735 | $154.63 | $158.59 | 259.18K |
| Oct 9, 2026 | $152.73 | $155.99 | $152.17 | $154.49 | 179.3K |
| Oct 8, 2026 | $155.79 | $155.85 | $150.21 | $152.52 | 154.4K |
| Oct 7, 2026 | $155.09 | $156.75 | $154.60 | $156.08 | 97.81K |
| Oct 6, 2026 | $158.24 | $158.24 | $152.64 | $155.61 | 190.26K |
Latest BLTE news
The latest Smart Investors Daily articles mentioning BLTE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BLTE research
Overview
Company profile and research snapshot.
Company profile
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $191.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 9, 2026 | Mizuho | Outperform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 14, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 9, 2026
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.
SeekingAlpha · Sep 9, 2026
Belite Bio On Track For A Potential Blockbuster Launch In 2027
Belite Bio is on track toward a potential blockbuster launch of tinlarebant in 2027, with FDA approval for STGD1 expected. Learn why BLTE stock is a hold.
Benzinga · Sep 8, 2026
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
